gemfibrozil has been researched along with probucol in 42 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 20 (47.62) | 18.7374 |
1990's | 13 (30.95) | 18.2507 |
2000's | 4 (9.52) | 29.6817 |
2010's | 4 (9.52) | 24.3611 |
2020's | 1 (2.38) | 2.80 |
Authors | Studies |
---|---|
Aizawa, Y; Fujita, T; Hasegawa, K; Horikoshi, H; Kanai, T; Kurumada, T; Yoshioka, T | 1 |
Topliss, JG; Yoshida, F | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
D'Amico, G; Gentile, MG | 1 |
Kłosiewicz-Latoszek, L; Szostak, WB | 1 |
Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK | 1 |
Shapiro, DR; Walker, JF | 1 |
Hunninghake, DB | 2 |
Islami, Y; Ribeiro, LG | 1 |
Naito, HK | 1 |
Davignon, J | 1 |
Blum, CB; Levy, RI | 1 |
Nikkilä, EA; Tikkanen, MJ | 1 |
Perry, RS | 1 |
Havel, RJ; Kane, JP | 1 |
Malinow, MR | 1 |
Gotto, AM; Jones, PH; Scott, LW | 1 |
Levy, RI; Schaefer, EJ | 1 |
Santafé Oroz, J; Segarra Domènech, J | 1 |
Nash, DT | 2 |
Glueck, C | 1 |
Kuo, PT | 1 |
Ades, EW; Lawley, TJ; Pruckler, JM | 1 |
Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M | 1 |
Bays, HE; Dujovne, CA | 1 |
Mendonça, CX; Mori, AV; Santos, CO | 1 |
Ando, N; Ashidate, K; Kaneko, K; Kawamura, M; Miyazaki, S; Teramoto, T; Thoda, H | 1 |
Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA | 1 |
Chen, L; Chen, SC; Tsui, L; Wu, SJ; Xie, W; Xu, S; Ye, P | 1 |
12 review(s) available for gemfibrozil and probucol
Article | Year |
---|---|
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit Analysis; Drug Therapy, Combination; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol; Sensitivity and Specificity | 1990 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipoproteinemias; Niacin; Probucol | 1990 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Male; Probucol; Triglycerides | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Niacin; Patient Education as Topic; Pentanoic Acids; Probucol | 1987 |
Contemporary recommendations for evaluating and treating hyperlipidemia.
Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Phenotype; Probucol | 1986 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Mice; Middle Aged; Neomycin; Niacin; Pentanoic Acids; Pregnancy; Probucol; Rats | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylomicrons; Colestipol; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Hypobetalipoproteinemias; Hypolipoproteinemias; Infant; Infant, Newborn; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Tangier Disease | 1985 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol | 1983 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides | 1984 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol | 1994 |
Drug interactions of lipid-altering drugs.
Topics: Contraindications; Drug Interactions; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Probucol; Resins, Plant | 1998 |
3 trial(s) available for gemfibrozil and probucol
Article | Year |
---|---|
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients.
Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lovastatin; Nephrotic Syndrome; Probucol | 1991 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Male; Probucol; Triglycerides | 1988 |
28 other study(ies) available for gemfibrozil and probucol
Article | Year |
---|---|
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
Topics: Animals; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Phenols; Rats; Structure-Activity Relationship | 1989 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Lovastatin; Neomycin; Niacin; Probucol | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol | 1991 |
Current and new therapy for hypercholesterolemia.
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Dietary Fats; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Niacin; Patient Compliance; Pentanoic Acids; Probucol; Risk Factors | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pentanoic Acids; Phenols; Probucol; Risk | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Probucol | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Adverse effects of the treatment for hyperlipidemia.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Physical Exertion; Probucol; Risk | 1986 |
Addition to labeling of cholestyramine.
Topics: Cholestyramine Resin; Clofibrate; Diet Therapy; Drug Labeling; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Pentanoic Acids; Probucol; Thyroxine; United States; United States Food and Drug Administration | 1985 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Neomycin; Niacin; Pentanoic Acids; Probucol; Triglycerides | 1985 |
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Triglycerides; Valerates | 1983 |
Influence of clofibrate, bile-sequestering agents and probucol on high-density lipoprotein levels.
Topics: Bile Acids and Salts; Clofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Nicotinic Acids; Pentanoic Acids; Phenols; Probucol | 1983 |
Hyperlipidemia: reducing the chances of cardiovascular disease.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pentanoic Acids; Probucol; Triglycerides | 1984 |
Use of a human microvascular endothelial cell line as a model system to evaluate cholesterol uptake.
Topics: Biological Transport; Cells, Cultured; Cholesterol; Cholestyramine Resin; Clofibrate; Endothelium, Vascular; Gemfibrozil; Humans; Models, Biological; Probucol; Tritium | 1993 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Probucol | 1993 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Female; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Immunosuppressive Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Lung Transplantation; Male; Middle Aged; Myocardial Ischemia; Probucol; Radionuclide Angiography; Retrospective Studies; Triglycerides; Ventricular Dysfunction, Left; Ventricular Function, Left | 1997 |
Effect of dietary lipid-lowering drugs upon plasma lipids and egg yolk cholesterol levels of laying hens.
Topics: Animals; Anticholesteremic Agents; Chickens; Cholesterol; Dietary Supplements; Egg Yolk; Female; Gemfibrozil; Lipids; Lovastatin; Probucol; Triglycerides | 1999 |
Gemfibrozil metabolite inhibits in vitro low-density lipoprotein (LDL) oxidation and diminishes cytotoxicity induced by oxidized LDL.
Topics: Antioxidants; Azo Compounds; Cell Line; Cell Survival; Copper; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Macrophages; Nitriles; Oxidation-Reduction; Pentanoic Acids; Phenols; Probucol | 2000 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids; Inflammation; Male; Metabolic Syndrome; Microcirculation; Muscle, Skeletal; Nitric Oxide; Probucol; Pyrroles; Rats; Rats, Zucker; Simvastatin; Time Factors | 2009 |
Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis.
Topics: Cholestyramine Resin; Drug-Related Side Effects and Adverse Reactions; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Probucol | 2023 |